Predicting Treatment Response in Non-Hodgkin's Lymphoma from the Pretreatment Tumor Content of Phosphoethanolamine Plus Phosphocholine

Academic Radiology

Volumn 11, Issue 4, 2004, Pages 368-376

  Arias Mendoza, Fernando ^a,b   Smith, Mitchell R ^a   Brown, Truman R ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b HATCH LTD   (Canada)

Author keywords

31P MR spectroscopy; Drug sensitivity resistance; In vivo metabolism; Non Hodgkin's lymphoma; Phospholipid intermediates; Treatment predictor

Indexed keywords

PHOSPHOETHANOLAMINE; PHOSPHORUS 31; PHOSPHORYLCHOLINE;

APOPTOSIS; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ERROR; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LONG TERM CARE; NONHODGKIN LYMPHOMA; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT FAILURE;

EID: 1642503015     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1076-6332(03)00721-9     Document Type: Article

References (30)

1. Smith MR. Non-Hodgkin's lymphoma. In: Williams SD, Goulet R, Thomas G, eds. Current Problems in Cancer. Vol. XX. St. Louis, MO: Mosby, 1966 1-80
2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329:987-994.
3. Ristamaki R, Joensuu H, Soderstrom KO, Jalkanen S. CD44v6 expression in non-Hodgkin's lymphoma: an association with low histological grade and poor prognosis. J Pathol 1995; 176:259-267.
4. Drillenburg P, Wielenga VJ, Kramer MH, et al. CD44 expression predicts disease outcome in localized large B cell lymphoma. Leukemia 1999; 13:1448-1455.
5. Inagaki H, Banno S, Wakita A, Ueda R, Eimoto T. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma. Mod Pathol 1999; 12:546-552.
6. Korkolopoulou P, Angelopoulou MK, Kontopidou F, et al. Prognostic implications of proliferating cell nuclear antigen (PCNA), AgNORs and P53 in non-Hodgkin's lymphomas. Leuk Lymphoma 1998; 30:625-636.
7. Moller MB, Gerdes AM, Skjodt K, Mortensen LS, Pedersen NT. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma. Clin Cancer Res 1999; 5:1085-1091.
8. Stauder R, Eisterer W, Thaler J, Gunthert U. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood 1995; 85:2885-2899.
9. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503-511.
10. Chott A, Augustin I, Wrba F, Hanak H, Ohlinger W, Radaszkiewicz T. Peripheral T-cell lymphomas: a clinicopathologic study of 75 cases. Hum Pathol 1990; 21:1117-1125.
11. Grogan TM, Lippman SM, Spier CM, et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 1988; 71:1157-1160.
12. Korkolopoulou P, Angelopoulou MK, Kontopidou F, et al. Prognostic relevance of apoptotic cell death in non-Hodgkin's lymphomas: a multivariate survival analysis including Ki67 and p53 oncoprotein expression. Histopathology 1998; 33:240-247.
13. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT. Leuk Lymphoma 2000; 39:543-553.
14. Front D, Bar-Shalom R, Mor M, et al. Aggressive non-Hodgkin lymphoma: early prediction of outcome with 67Ga scintigraphy. Radiology 2000; 214:253-257.
15. Sun SS, Tsai SC, Wang JJ, Ho YJ, Ho ST, Kao CH. Technetium-99m-tetrofosmin scintigraphy in the prediction of chemotherapy response of untreated malignant lymphomas and comparison with other prognostic factors. Anticancer Res 2001; 21:685-688.
16. Griffiths JR, Cady E, Edwards RH, McCready VR, Wilkie DR, Wiltshaw E. 31P-NMR studies of a human tumour in situ. Lancet 1983; 1:1435-1436.
17. Griffiths JR, Tate AR, Howe FA, Stubbs M. Magnetic Resonance Spectroscopy of cancer-practicalities of multi-centre trials and early results in non-Hodgkin's lymphoma. Eur J Cancer 2002; 36:2085.
18. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 1992; 5:303-324.
19. Negendank WG, Padavic-Shaller KA, Li CW, et al. Metabolic characterization of human non-Hodgkin's lymphomas in vivo with the use of proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res 1995; 55:3286-3294.
20. Li CW, Kuesel AC, Padavic-Shaller KA, et al. Metabolic characterization of human soft tissue sarcomas in vivo and in vitro using proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res 1996; 56:2964-2972.
21. Vigneron DB, Nelson SJ, Murphy-Boesch J, et al. Chemical shift imaging of human brain: axial, sagittal, and coronal P-31 metabolite images. Radiology 1990; 177:643-649.
22. Murphy-Boesch J, Stoyanova R, Srinivasan R, et al. Proton-decoupled 31P chemical shift imaging of the human brain in normal volunteers. NMR Biomed 1993; 6:173-180.
23. Murphy-Boesch J, Srinivasan R, Carvajal L, Brown TR. Two configurations of the four-ring birdcage coil for 1H imaging and 1H-decoupled 31P spectroscopy of the human head. J Magn Reson B 1994; 103: 103-114.
24. Hu J, Javaid T, Arias-Mendoza F, Liu Z, McNamara R, Brown TR. A fast, reliable, automatic shimming procedure using 1H chemical-shift-imaging spectroscopy. J Magn Reson B 1995; 108:213-219.
25. Agarwal ML, Larkin HE, Zaidi SI, Mukhtar H, Oleinick NL. Phospholipase activation triggers apoptosis in photosensitized mouse lymphoma cells. Cancer Res 1993; 53:5897-5902.
26. Ferguson JE, Hanley MR. The role of phospholipases and phospholipid-derived signals in cell activation. Curr Opin Cell Biol 1991; 3:206-122.
27. Warden CH, Friedkin M. Regulation of choline kinase activity and phosphatidylcholine biosynthesis by mitogenic growth factors in 3T3 fibroblasts. J Biol Chem 1985; 260:6006-6011.
28. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49:2112-2135.
29. Chabner BA, Fisher RI, Young RC, DeVita VT. Staging of non-Hodgkin's lymphoma. Semin Oncol 1980; 7:285-291.
30. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89:3909-3918.